TSE

SYLA Technologies Enters into Basic Agreement Regarding a Business Alliance with RIBERESUTE and Agrees to Acquire Shares from Four of Its Shareholders to Become the Largest Shareholder

Retrieved on: 
Wednesday, November 15, 2023

SYLA expects that the Share Acquisition will make it the largest shareholder of RIBERESUTE.

Key Points: 
  • SYLA expects that the Share Acquisition will make it the largest shareholder of RIBERESUTE.
  • The Share Acquisition is subject to certain closing conditions and is expected to be completed by mid-January 2024.
  • In conjunction with this Share Acquisition, SYLA today has also entered into a "Basic Agreement on Business Alliance" (the "Agreement") with RIBERESUTE.
  • The envisioned details of the business alliance at this time are as follows:

Advantest Rolls Out Pin Scale Multilevel Serial – Next-Generation High-Speed ATE Instrument

Retrieved on: 
Tuesday, November 14, 2023

TOKYO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857) today announced Pin Scale Multilevel Serial, its newest high-speed I/O (HSIO) instrument.

Key Points: 
  • TOKYO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857) today announced Pin Scale Multilevel Serial, its newest high-speed I/O (HSIO) instrument.
  • Designed for use with the V93000 EXA Scale ATE platform, Pin Scale Multilevel Serial is both the first native EXA Scale HSIO instrument and the first fully integrated HSIO ATE instrument to address signaling requirements for advanced communication interfaces.
  • Because Pin Scale Multilevel Serial is fully integrated, it can be easily configured into the EXA Scale platform.
  • To learn more about Pin Scale Multilevel Serial and the V93000 EXA Scale™ test platform, please visit https://www.advantest.com/products/soc/v93000/exa.html .

ISE Labs Chooses Advantest’s V93000 EXA Scale™ SoC Test System for Production Test Services

Retrieved on: 
Monday, November 13, 2023

TOKYO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857) today announced that longtime customer ISE Labs (Fremont, Calif.) has purchased a V93000 EXA Scale SoC Test System.

Key Points: 
  • TOKYO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857) today announced that longtime customer ISE Labs (Fremont, Calif.) has purchased a V93000 EXA Scale SoC Test System.
  • The EXA Scale system joins existing earlier-generation V93000 systems on ISE Labs’ 24/7 test floor, where the company provides production test services for digital, mixed-signal, analog, RF and SoC devices on a wide variety of test platforms.
  • EXA Scale is fully compatible with ISE Labs’ existing V93000 systems, load boards and test instruments, allowing the test house to smoothly transition to the EXA Scale generation while optimizing the utilization of its test resources.
  • This move to EXA Scale expands our relationship with ISE Labs and enables them to leverage their proven production test capabilities for new markets.”
    Launched in 2000, the flexible, scalable V93000 is Advantest's flagship SoC test platform.

Nippon Steel Corporation (NSC) to Acquire U. S. Steel, Moving Forward Together as the ‘Best Steelmaker with World-Leading Capabilities’

Retrieved on: 
Monday, December 18, 2023

The transaction has been unanimously approved by the Board of Directors of both NSC and U. S. Steel.

Key Points: 
  • The transaction has been unanimously approved by the Board of Directors of both NSC and U. S. Steel.
  • For customers, U. S. Steel and NSC create a truly global steel company with combined capabilities and innovation capable of meeting our customers’ evolving needs.
  • U. S. Steel has long been one of America’s steel industry leaders, while NSC has been serving U.S. customers successfully for decades.
  • Milbank LLP and Wachtell, Lipton, Rosen & Katz are acting as legal advisors to U. S. Steel.

Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes

Retrieved on: 
Monday, December 18, 2023

Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo and AstraZeneca.

Key Points: 
  • Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo and AstraZeneca.
  • TROPION-Breast04 is evaluating neoadjuvant datopotamab deruxtecan plus durvalumab followed by adjuvant durvalumab with or without chemotherapy in patients with stage II-III triple negative breast cancer (TNBC) or hormone receptor (HR) low, HER2 low or negative breast cancer.
  • TROPION-Breast05 is evaluating datopotamab deruxtecan alone and in combination with durvalumab in patients with locally recurrent inoperable or metastatic TNBC whose tumors express PD-L1 (CPS ≥ 10).
  • TROPION-Breast03 is evaluating datopotamab deruxtecan with and without durvalumab versus investigator’s choice of therapy in patients with stage I to III TNBC with residual disease after neoadjuvant therapy.

U.S. FDA Grants Orphan Drug Designation to JR-441 for the Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)

Retrieved on: 
Friday, December 15, 2023

JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced that the U.S. Food and Drug Administration (“FDA”) granted orphan drug designation (ODD) to JR-441, an investigational drug for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA, or Sanfilippo syndrome type A).

Key Points: 
  • JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced that the U.S. Food and Drug Administration (“FDA”) granted orphan drug designation (ODD) to JR-441, an investigational drug for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA, or Sanfilippo syndrome type A).
  • JR-441 is a blood-brain barrier (BBB)-penetrating form of recombinant heparan N-sulfatase that was developed using JCR’s proprietary J-Brain Cargo® BBB-penetrating technology.
  • JCR is currently conducting a global Phase I/II clinical trial for JR-441, with the first patient with MPS IIIA dosed in October 2023.
  • We look forward to advancing JR-441 in clinical development and bringing this very important treatment to patients with MPS IIIA as quickly and safely as possible."

Imperial announces preliminary results of its substantial issuer bid

Retrieved on: 
Monday, December 11, 2023

Imperial Oil Limited (TSE: IMO, NYSE American: IMO) announced today the preliminary results of its substantial issuer bid (the “Offer”), pursuant to which Imperial offered to purchase for cancellation up to $1.5 billion of its common shares (the “Shares”).

Key Points: 
  • Imperial Oil Limited (TSE: IMO, NYSE American: IMO) announced today the preliminary results of its substantial issuer bid (the “Offer”), pursuant to which Imperial offered to purchase for cancellation up to $1.5 billion of its common shares (the “Shares”).
  • Immediately following completion of the Offer, Imperial anticipates that 535,836,803 Shares will be issued and outstanding.
  • 27,768,599 Shares were validly tendered and not withdrawn pursuant to auction tenders at or below the Purchase Price and pursuant to purchase price tenders.
  • Shareholders who made auction tenders at a price in excess of the Purchase Price should not expect to have any of their Shares purchased by Imperial.

New Trinseo PMMA Depolymerization Plant Reimagines Plastics Value Chain With Sustainability In Mind

Retrieved on: 
Wednesday, December 6, 2023

Trinseo (“Trinseo” or “the Company”) (NYSE: TSE), a specialty material solutions provider, is helping advance the potential of sustainable plastics with the inauguration of its next generation, polymethyl methacrylate (PMMA) depolymerization plant in Rho, Italy.

Key Points: 
  • Trinseo (“Trinseo” or “the Company”) (NYSE: TSE), a specialty material solutions provider, is helping advance the potential of sustainable plastics with the inauguration of its next generation, polymethyl methacrylate (PMMA) depolymerization plant in Rho, Italy.
  • PMMA, renowned for its versatility in various applications, will be transformed through this advanced recycling and purification process where it can go back into the plastics value chain and support the goal of circularity.
  • Trinseo’s depolymerization facility is being developed around a continuous recovery model to produce high quality recycled PMMA that matches the quality of its virgin counterpart, promoting a circular plastics value chain without compromising performance.
  • A shift towards PMMA depolymerization can help deliver sustainability benefits for consumers, manufacturers, and industries alike.

DNA Plc Automates New Data Centers with Juniper Networks® and NEC

Retrieved on: 
Tuesday, December 12, 2023

DNA’s new data center infrastructure provides a unified platform for both its business-to-business customer services and internal IT services.

Key Points: 
  • DNA’s new data center infrastructure provides a unified platform for both its business-to-business customer services and internal IT services.
  • By automating the data center network, DNA can eliminate human error, optimize its technical team’s workload to focus on service creation and simplify first-class service delivery at scale.
  • DNA has selected the Juniper Apstra solution as the data center infrastructure’s foundation: unique, intent-based networking software that simplifies, automates and validates data center design, planning and operations, from Day 0 to Day 2+.
  • DNA also deployed Juniper Networks QFX Series Switches across its new data center fabric.

Daiichi Sankyo Demonstrates Breadth and Depth of Oncology Portfolio Across Multiple Cancers with New Data at ESMO Asia, SABCS and ASH

Retrieved on: 
Friday, December 1, 2023

Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio in multiple types of solid and blood cancers at the 2023 ESMO Asia Congress (#ESMOAsia23), San Antonio Breast Cancer Symposium (#SABCS23) and American Society of Hematology (#ASH23) Annual Meeting prior to its annual R&D Day.

Key Points: 
  • Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio in multiple types of solid and blood cancers at the 2023 ESMO Asia Congress (#ESMOAsia23), San Antonio Breast Cancer Symposium (#SABCS23) and American Society of Hematology (#ASH23) Annual Meeting prior to its annual R&D Day.
  • “Our goal is to push the boundaries of science to change the way cancer is treated,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo.
  • Daiichi Sankyo will hold its annual R&D Day for investors, analysts and media on Monday, December 11 at 5:30 - 7:00 pm EST/Tuesday, December 12 at 7:30 - 9:00 am JST.
  • Company executives will provide highlights of Daiichi Sankyo’s research data presented at SABCS and ASH, as well as updates on the company’s R&D strategy.